Efficacy and safety of SYH2053 in patients with primary hypercholesterolemia or mixed dyslipidemia: a phase II, multicenter, randomized, double-blind, placebo- and active-controlled trial
SYH2053 is a novel small interfering RNA (siRNA) drug targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), with optimized full-sequence chemical modification and N-acetylgalactosamine conjugation, which demonstrated a stable and sustained lipid-lowering efficacy in the phase I study in heathy particip...